Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

22.08.2024 | short review

Acute lymphoblastic leukemia at the 2023 ASH meeting

Real-world data from CAR T-cells, pediatric-inspired protocols for young adults, chemotherapy-free combinations, and first-line immunotherapy

verfasst von: PD Dr. Alexandra Böhm

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Summary

The annual congress of the American Society of Hematology (ASH) in San Diego in 2023 was very well attended for the first time since the pandemic. In the following article, a brief summary of the highlights regarding acute lymphoblastic leukemia is presented. There were two main focuses in the education sessions: CAR T‑cells and the role of allogeneic stem cell transplantation, and the optimal treatment of adolescents and young adults patients. The oral and poster sessions provided exciting and clinically important data on the following: CAR T‑cells—real-world data; blinatumomab and inotuzumab as first-line therapy; chemo-free combinations for Philadelphia-chromosome-positive acute lymphoblastic leukemia (ALL), long-term side effects of total body irradiation, and new treatment options with venetoclax or revumenib.
Vorheriger Artikel 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives
Nächster Artikel Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment
Literatur
1.
Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B‑cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502.CrossRefPubMed
2.
Laetsch TW, Maude SL, Rives S, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41:1664–9.CrossRefPubMed
3.
Bezerra E, Itani T, Wudhikarn K, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) adult B‑cell acute lymphoblastic leukemia (B-cell ALL): evidence from the CIBMTR registry. In: ASH Meeting. Vol. 1029. 2023.
4.
Roloff GW, Aldoss I, Kopmar NE, et al. Brexucabtagene autoleucel in adults with relapsed/refractory B‑cell ALL: outcomes and novel insights from the real-world outcomes collaborative of CAR T in adult ALL (ROCCA). In: ASH meeting. Abstract, Vol. 1030. 2023.
5.
Goekbuget N, Schwartz S, Faul C, et al. Updated results from a phase II study of hyper-CVAD, with or without Inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B‑cell acute lymphoblastic leukemia. In: ASH meeting. Abstract, Vol. 4245. 2023.
6.
Nguyen D, Kantarjian HM, Short NJ, et al. Updated results from a phase II study of hyper-CVAD, with or without Inotuzumab ozogamicin, and sequential blinatumomab in patients with newly diagnosed B‑cell acute lymphoblastic leukemia. In: ASH meeting. Vol. 4245. 2023.
7.
Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24–e34.CrossRefPubMed
8.
Haddad FG, Jabbour E, Short NJ, et al. Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed philadelphia chromosome—positive acute lymphoblastic leukemia: updates from a phase II. In: ASH meeting. Vol. 2827. 2023.
9.
Fransecky L, Fiedler W, Röllig C, et al. Venetoclax and blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B‑precursor all: first results of the GMALL-Bliven trial. In: ASH meeting. Abstract, Vol. 1502. 2023.
10.
Luskin MR, Shimony S, Keating J, et al. A phase I study of venetoclax in combination with Inotuzumab ozogamicin for relapsed or refractory all in adults. In: ASH meeting. Abstract, Vol. 1509. 2023.
11.
Aldoss I, Ghayas CI, Thirman M, et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study. LBA‑5. In: ASH meeting. 2023.
12.
Peters C, Dalle JH, Locatelli F, et al. EBMT Paediatric diseases working party. Total body irradiation or chemotherapy conditioning in childhood all: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307.CrossRefPubMed
13.
Lawitschka A, Dalle J‑H, Pötschger U, et al. Moderate incidence but striking correlation with TBI of secondary malignancies after HSCT in children with all: long-term follow-up from the prospective international BFM- and forum-trials. In: ASH meeting. Vol. 110. 2023.
Metadaten
Titel
Acute lymphoblastic leukemia at the 2023 ASH meeting
Real-world data from CAR T-cells, pediatric-inspired protocols for young adults, chemotherapy-free combinations, and first-line immunotherapy
verfasst von
PD Dr. Alexandra Böhm
Publikationsdatum
22.08.2024
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-024-00985-7

Weitere Artikel der Ausgabe 3/2024

ASH 2023

  • editorial

Trends in MDS and AML from ASH 2023

  • short review

Seminal vesicle metastasis from transverse colon adenocarcinoma: a unique case report

  • Open Access
  • case report

Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023

  • Open Access
  • short review

Molecular tumor board—editorial

  • editorial

Advanced stage Hodgkinʼs lymphoma 2024—Update on first line treatment

  • short review